Bone marrow mesenchymal stem cell-derived exosomes induce the Th17/Treg imbalance in immune thrombocytopenia through miR-146a-5p/IRAK1 axis

• DOI: 10.1007/s13577-021-00547-7
• Publication Date: 2021-07-06T09:04:02Z
• Authors: Yue He; Dexiang Ji; Wei Lu; Fei Li; Xianbao Huang; Ruibin Huang; Guoan Chen
• Keywords: Purpura, Thrombocytopenic, Idiopathic; 0303 health sciences; Gene Expression; Bone Marrow Cells; Mesenchymal Stem Cells; Exosomes; T-Lymphocytes, Regulatory; 3. Good health; MicroRNAs; 03 medical and health sciences; Interleukin-1 Receptor-Associated Kinases; Humans; Th17 Cells; Molecular Targeted Therapy; Cells, Cultured

Bone marrow mesenchymal stem cells (BMSCs) are associated with immune thrombocytopenia (ITP), the underlying mechanism has not been fully elucidated. Here, we attempted to investigate whether BMSCs can regulate Th17/Treg imbalance in ITP through the exosome pathway. We first assessed the proportions of Th17 cells and Tregs in ITP patients, showing that ITP patients exhibited an evident imbalance of Th17/Treg. BMSCs-exosomes' treatment significantly reduced Th17/Treg ratio in the CD4+ T cells of ITP patients. Moreover, miR-146a-5p was highly expressed in BMSCs-exosomes. The expression of miR-146a-5p was obviously increased in CD4+ T cells following the treatment of BMSCs-exosomes. BMSCs-exosomal miR-146a-5p silencing promoted the proportions of Th17 cells and repressed the proportions of Tregs in CD4+ T cells. In addition, miR-146a-5p directly interacted with IL-1R-associated kinase-1 (IRAK), and repressed IRAK1 expression. IRAK1 overexpression promoted Th17/Treg ratio in CD4+ T cells, which was abolished by BMSCs-exosomal miR-146a-5p. In conclusion, these findings demonstrate that BMSC-derived exosomal miR-146a-5p regulates Th17/Treg imbalance in ITP by repressing IRAK1 expression. Thus, this work suggests that BMSCs-exosomal miR-146a-5p may be a potential therapeutic target for ITP.